カテゴリ： Bahamas, GlobalData, 企業調査

Nymox Pharmaceutical Corp (NYMX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Nymox Pharmaceutical Corp (NYMX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10056
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：75
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：Bahamas
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that undertakes the research and development of therapeutics and diagnostics devices to target the unmet needs of the aging population. The company markets diagnostic products for measuring tobacco product exposure and for the diagnosis of Alzheimer’s disease. Its diagnostic product portfolio includes NicAlert test to determine smoking status; and TobacAlert home test to determine person’s level of exposure to tobacco products, including second hand smoke. Nymox’s lead drug candidate, NX-1207 intended for the treatment of BPH (benign prostatic hyperplasia) and certain types of cancer. It has subsidiaries in New Jersey, the US. Nymox is headquartered in Nassau, the Bahamas.

Nymox Pharmaceutical Corp (NYMX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Nymox Pharmaceutical Corp, Medical Devices Deals, 2012 to YTD 2018 11
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deal Details 15
Equity Offering 15
Nymox Pharma Raises USD16.3 Million in Private Placement of Shares 15
Nymox Pharma Raises USD3 Million in Private Placement of Shares 16
Nymox Pharma Raises USD2.24 Million in Private Placement of Shares 17
Nymox Pharma Raises Additional USD2.1 Million in Private Placement of Shares 18
Nymox Pharmaceutical to Raise USD12 Million in Private Placement 19
Nymox Pharma Raises USD0.8 Million in Private Placement of Shares 20
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 21
Nymox Pharma Raises USD0.59 Million in Private Placement of Shares 22
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 23
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 24
Nymox Pharma Raises USD0.25 Million in Private Placement of Shares 25
Nymox Pharma Raises USD0.15 Million in Private Placement of Shares 26
Nymox Pharma Raises USD0.15 million in Private Placement of Shares 27
Nymox Pharma Raises USD0.15 Million in Private Placement of Shares 28
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 29
Nymox Pharma Raises USD0.3 million in Private Placement of Shares 30
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 31
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 32
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 33
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 34
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 35
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 36
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 37
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 38
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 39
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 40
Nymox Pharma Raises USD0.3 million in Private Placement of Shares 41
Nymox Pharma Raises USD0.14 Million in Private Placement of Shares 42
Nymox Pharma Raises USD0.15 Million in Public Offering of Shares 43
Nymox Pharma Raises USD0.35 Million in Public Offering of Shares 44
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 45
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 46
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 47
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 48
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 49
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 50
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 51
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 52
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 53
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 54
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 55
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 56
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 57
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 58
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 59
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 60
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 61
Nymox Pharma Raises USD1.1 Million in Private Placement of Shares 62
Nymox Pharma Raises USD1 Million in Private Placement of Shares 63
Nymox Pharma Completes Private Placement Of Shares For US$15 Million 64
Nymox Pharma Raises USD1 Million in Private Placement of Shares 65
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 66
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 67
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 68
Nymox Pharma Raises USD1 Million in Private Placement of Shares 69
Debt Offering 70
Nymox Pharma Raises USD1.1 Million in Public Offering of Debenture 70
Nymox Pharmaceutical Corp – Key Competitors 71
Nymox Pharmaceutical Corp – Key Employees 72
Nymox Pharmaceutical Corp – Locations And Subsidiaries 73
Head Office 73
Other Locations & Subsidiaries 73
Recent Developments 74
Other Significant Developments 74
Jul 02, 2018: NYMOX Announces Expanded Marketing Plans 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75

List of Tables
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Nymox Pharmaceutical Corp, Deals By Therapy Area, 2012 to YTD 2018 10
Nymox Pharmaceutical Corp, Medical Devices Deals, 2012 to YTD 2018 11
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Nymox Pharma Raises USD16.3 Million in Private Placement of Shares 15
Nymox Pharma Raises USD3 Million in Private Placement of Shares 16
Nymox Pharma Raises USD2.24 Million in Private Placement of Shares 17
Nymox Pharma Raises Additional USD2.1 Million in Private Placement of Shares 18
Nymox Pharmaceutical to Raise USD12 Million in Private Placement 19
Nymox Pharma Raises USD0.8 Million in Private Placement of Shares 20
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 21
Nymox Pharma Raises USD0.59 Million in Private Placement of Shares 22
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 23
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 24
Nymox Pharma Raises USD0.25 Million in Private Placement of Shares 25
Nymox Pharma Raises USD0.15 Million in Private Placement of Shares 26
Nymox Pharma Raises USD0.15 million in Private Placement of Shares 27
Nymox Pharma Raises USD0.15 Million in Private Placement of Shares 28
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 29
Nymox Pharma Raises USD0.3 million in Private Placement of Shares 30
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 31
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 32
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 33
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 34
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 35
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 36
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 37
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 38
Nymox Pharma Raises USD0.1 Million in Private Placement of Shares 39
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 40
Nymox Pharma Raises USD0.3 million in Private Placement of Shares 41
Nymox Pharma Raises USD0.14 Million in Private Placement of Shares 42
Nymox Pharma Raises USD0.15 Million in Public Offering of Shares 43
Nymox Pharma Raises USD0.35 Million in Public Offering of Shares 44
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 45
Nymox Pharma Raises USD0.35 Million in Private Placement of Shares 46
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 47
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 48
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 49
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 50
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 51
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 52
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 53
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 54
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 55
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 56
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 57
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 58
Nymox Pharma Raises USD0.3 Million in Private Placement of Shares 59
Nymox Pharma Raises USD0.4 Million in Private Placement of Shares 60
Nymox Pharma Raises USD0.2 Million in Private Placement of Shares 61
Nymox Pharma Raises USD1.1 Million in Private Placement of Shares 62
Nymox Pharma Raises USD1 Million in Private Placement of Shares 63
Nymox Pharma Completes Private Placement Of Shares For US$15 Million 64
Nymox Pharma Raises USD1 Million in Private Placement of Shares 65
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 66
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 67
Nymox Pharma Raises USD0.5 Million in Private Placement of Shares 68
Nymox Pharma Raises USD1 Million in Private Placement of Shares 69
Nymox Pharma Raises USD1.1 Million in Public Offering of Debenture 70
Nymox Pharmaceutical Corp, Key Competitors 71
Nymox Pharmaceutical Corp, Key Employees 72
Nymox Pharmaceutical Corp, Subsidiaries 73

List of Figures
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Nymox Pharmaceutical Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Nymox Pharmaceutical Corp, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Nymox Pharmaceutical Corp (NYMX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • The Toro Company：戦略・SWOT・企業財務分析
    The Toro Company - Strategy, SWOT and Corporate Finance Report Summary The Toro Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • NVR Inc：戦略・SWOT・企業財務分析
    NVR Inc - Strategy, SWOT and Corporate Finance Report Summary NVR Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • TOA Corporation：企業の戦略・SWOT・財務情報
    TOA Corporation - Strategy, SWOT and Corporate Finance Report Summary TOA Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Dolphin Drilling A.S.A. (FOE)：企業の財務・戦略的SWOT分析
    Summary Dolphin Drilling ASA (Dolphin Drilling) is an oil and gas company that offers drilling contract and deep water services. The company's services include exploration and production services, repair services, fleet operations and management, pressure drilling, and deep water drilling services. …
  • Hamilton Thorne Ltd (HTL)：医療機器：M&Aディール及び事業提携情報
    Summary Hamilton Thorne Ltd (Hamilton Thorne) is a medical equipment company that offers precision laser devices and advanced image analysis systems. The company's products include clinical lasers, animal and research sperm analysis products, research lasers, clinical sperm analysis products, sperm …
  • Empresas Publicas De Medellin ESP：企業の戦略的SWOT分析
    Empresas Publicas De Medellin ESP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • VolitionRX Ltd (VNRX)：製薬・医療：M&Aディール及び事業提携情報
    Summary VolitionRX Ltd (VolitionRX) is a medical equipment provider that develops diagnostics tests for cancer and other conditions. The company develops Nucleosomics, a platform technology used for measurement and identification of nucleosomes in the blood. It develops tools for the diagnosis of va …
  • UK Green Investment Bank Ltd：電力：M&Aディール及び事業提携情報
    Summary UK Green Investment Bank Ltd (UK Green) is an investment firm that offers green infrastructure investment services in the UK. The firm primarily invests on renewable energy and energy efficiency projects that include offshore wind, green deals and waste and bio energy and onshore renewable e …
  • Advanced Biological Laboratories SA：製薬・医療：M&Aディール及び事業提携情報
    Summary Advanced Biological Laboratories SA (ABL) is a medical data technology company that provides integrated software solutions for personalised medicine. The company offers TherapyEdge, a point of care, decision support software for healthcare professionals; and TherapyEdge Box systems, a web ba …
  • Bumi Armada Bhd (ARMADA)：石油・ガス：M&Aディール及び事業提携情報
    Summary Bumi Armada Bhd (Bumi Armada) is an integrated offshore solutions provider. The company owns and operates Floating Production Storage & Offloading (FPSO), Offshore Support Vessels (OSV), pipelaying barges, and subsea vessels. Its FPSO portfolio includes Armada TGT 1, Armada Sterling, Armada …
  • RAK Petroleum Plc (RAKP)：企業の財務・戦略的SWOT分析
    Summary RAK Petroleum Plc (RAK Petroleum), a subsidiary of RAK Investment Auhtority, is oil and gas company that transports and trades oil, gas and petrochemicals. The company carries out upstream, midstream and downstream activities. It operates its projects in the Middle East and Africa. RAK Petro …
  • Black River Electric Cooperative Inc：企業の戦略的SWOT分析
    Black River Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • TC Pipelines LP (TCP)：石油・ガス：M&Aディール及び事業提携情報
    Summary TC Pipelines LP (TC Pipelines) is an oil and gas company that manages natural gas pipelines and related assets. The company offers development and operation of North American energy infrastructure including natural gas and liquids pipelines, power generation and gas storage facilities. It op …
  • Vior Inc (VIO)：企業の財務・戦略的SWOT分析
    Summary Vior Inc (Vior) is a mining and mineral exploration company. The company carries out the business of acquisition, exploration, and development of gold and silver metal properties in North and Latin America. Its projects comprise Mosseau Gold project, Foothills Rutile project, Vezza-Noyard Go …
  • Molson Coors Brewing Co (TAP)：企業の財務・戦略的SWOT分析
    Molson Coors Brewing Co (TAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Wotif.com Holdings Limited：企業の戦略・SWOT・財務分析
    Wotif.com Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Wotif.com Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • GP Batteries International Ltd：企業の戦略的SWOT分析
    GP Batteries International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Nordic Nanovector ASA (NANO)：製薬・医療：M&Aディール及び事業提携情報
    Summary Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of haematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed fo …
  • American Gene Technologies International Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary American Gene Technologies International Inc (AGT) is a drug development company that tests and commercializes gene-based drugs. The company develops therapies for the treatment of cancer, neurological disorders, AIDS, infectious diseases, Parkinson’s diseases, diabetes, familial dysautonomi …
  • LBT Innovations Limited (LBT)：製品パイプライン分析
    Summary LBT Innovations Limited (LBT) is a medical device company that designs, develops and commercializes various products and automation technologies for the preparation and analysis of microbiology culture specimens, and microbiology and diagnostic laboratory services. It offers MicroStreak tech …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆